Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more
Market Cap & Net Worth: Gan & Lee Pharmaceuticals Co Ltd (603087)
Gan & Lee Pharmaceuticals Co Ltd (SHG:603087) has a market capitalization of $5.06 Billion (CN¥37.11 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #4214 globally and #410 in its home market, demonstrating a 0.06% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gan & Lee Pharmaceuticals Co Ltd's stock price CN¥62.13 by its total outstanding shares 597304969 (597.30 Million).
Gan & Lee Pharmaceuticals Co Ltd Market Cap History: 2020 to 2026
Gan & Lee Pharmaceuticals Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $10.66 Billion to $5.06 Billion (-0.60% CAGR).
Gan & Lee Pharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gan & Lee Pharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.18x
Gan & Lee Pharmaceuticals Co Ltd's market cap is 1.18 times its annual revenue
169.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
5.84x
Gan & Lee Pharmaceuticals Co Ltd's market cap is 5.84 times its annual earnings
862.31x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $10.66 Billion | $3.36 Billion | $1.23 Billion | 3.17x | 8.66x |
| 2021 | $5.69 Billion | $3.61 Billion | $1.45 Billion | 1.58x | 3.92x |
| 2022 | $2.65 Billion | $1.71 Billion | -$439.52 Million | 1.55x | N/A |
| 2023 | $4.29 Billion | $2.61 Billion | $340.07 Million | 1.64x | 12.60x |
| 2024 | $3.59 Billion | $3.05 Billion | $614.66 Million | 1.18x | 5.84x |
Competitor Companies of 603087 by Market Capitalization
Companies near Gan & Lee Pharmaceuticals Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Gan & Lee Pharmaceuticals Co Ltd by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #98 globally with a market cap of $170.40 Billion USD.
- EssilorLuxottica Société anonyme (PINK:ESLOF): Ranked #263 globally with a market cap of $78.22 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #362 globally with a market cap of $61.18 Billion USD ( €59.61 Billion EUR).
- Becton Dickinson and Company (NYSE:BDX): Ranked #472 globally with a market cap of $45.90 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #98 | Intuitive Surgical Inc | NASDAQ:ISRG | $170.40 Billion | $482.76 |
| #263 | EssilorLuxottica Société anonyme | PINK:ESLOF | $78.22 Billion | $265.00 |
| #362 | EssilorLuxottica S. A. | PA:EL | $61.18 Billion | €203.00 |
| #472 | Becton Dickinson and Company | NYSE:BDX | $45.90 Billion | $161.64 |
Gan & Lee Pharmaceuticals Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Gan & Lee Pharmaceuticals Co Ltd's market cap moved from $10.66 Billion to $ 5.06 Billion, with a yearly change of -0.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥5.06 Billion | -8.73% |
| 2025 | CN¥5.54 Billion | +54.35% |
| 2024 | CN¥3.59 Billion | -16.24% |
| 2023 | CN¥4.29 Billion | +61.60% |
| 2022 | CN¥2.65 Billion | -53.38% |
| 2021 | CN¥5.69 Billion | -46.63% |
| 2020 | CN¥10.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Gan & Lee Pharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.06 Billion USD |
| MoneyControl | $5.06 Billion USD |
| MarketWatch | $5.06 Billion USD |
| marketcap.company | $5.06 Billion USD |
| Reuters | $5.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.